BSX
Boston Scientific·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BSX
Boston Scientific Corporation
A global medical technology leader that develops medical devices for Cardiovascular, Rhythm Management, MedSurg and other interventional products
Healthcare Equipment and Supplies
--
05/22/1992
New York Stock Exchange
53,000
12-31
Common stock
300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234
Manufacturing and sales of medical devices
The history of Boston Scientific Corporation began in the late 1960's. The company is a global developer, manufacturer and marketer of medical devices that are widely used in the interventional medical profession. The company's endoscopy business develops and manufactures devices for the diagnosis and treatment of invasive and minimally invasive technologies to diagnose and treat a wide range of gastrointestinal and pulmonary diseases. The Urology and Pelvic Health business develops and manufactures devices for the treatment of various urinary and pelvic diseases in both male and female anatomy, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction, incontinence, pelvic floor disorders, abnormal uterine bleeding, and uterine fibroids and polyps. The company's heart rhythm management (CRM) business develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Company's electrophysiology business develops and manufactures minimally invasive medical technologies for the diagnosis and treatment of cardiac rate and rhythm disorders, including a wide range of therapeutic and diagnostic catheter products and a variety of devices used in electrophysiology laboratories. The Company's Neuromodulation business develops and manufactures devices for the treatment of various neurological movement disorders and the management of chronic pain. The company's interventional cardiology business develops, manufactures and commercializes technologies for the diagnosis and treatment of coronary artery disease and other cardiovascular diseases, including structural heart disease.
Earnings Call
Q1/2025
Estimate EPS0.67
Actual EPS0.75
Estimate Revenue4.57B
Actual Revenue4.66B
Elutia's Q1 2025: Key Contradictions on Manufacturing, Revenue, and Cash Flow
May 19,2025 09:13
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BSX has released its 2025 Q3 earnings. EPS was reported at 0.75, versus the expected 0.71, beating expectations. The chart below visualizes how BSX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BSX has released its 2025 Q3 earnings report, with revenue of 5.07B, reflecting a YoY change of 20.34%, and net profit of 755.00M, showing a YoY change of 61.32%. The Sankey diagram below clearly presents BSX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
